CHMP nod for two MicardisPlus generics and generic Ebixa
This article was originally published in Scrip
The European Medicines Agency's scientific advisory board, the CHMP, has given the go-ahead for three generic drugs: both Krka and Actavis' versions of Boehringer Ingelheim's MicardisPlus (telmisartan plus hydrochlorothiazide) and Krka's version of Lundbeck's Ebixa (memantine).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.